Rhythm Pharmaceuticals (RYTM) News Today $62.71 -1.70 (-2.64%) Closing price 04:00 PM EasternExtended Trading$61.18 -1.53 (-2.44%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Rhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesMay 6 at 8:00 AM | globenewswire.comBaker BROS. Advisors LP Sells 314,117 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Baker BROS. Advisors LP lessened its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 4.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 6,084,249 shares of the company's stock after selling 314,117 shares during the period. RhMay 6 at 7:39 AM | marketbeat.comBellevue Group AG Purchases 7,896 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Bellevue Group AG boosted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 50.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,596 shares of the company's stock after acquiring an addMay 6 at 6:33 AM | marketbeat.comSchonfeld Strategic Advisors LLC Acquires 29,165 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Schonfeld Strategic Advisors LLC grew its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 95.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 59,700 shares of the company's stock after buying an aMay 6 at 4:48 AM | marketbeat.comTower Research Capital LLC TRC Acquires 4,161 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Tower Research Capital LLC TRC increased its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 1,100.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,539 shares of the company's stock afterMay 6 at 3:51 AM | marketbeat.comAquatic Capital Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Aquatic Capital Management LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,223 shares of the company's stock,May 4 at 4:37 AM | marketbeat.comVoya Investment Management LLC Sells 5,663 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Voya Investment Management LLC reduced its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,169 shares of the company'sMay 3 at 4:47 AM | marketbeat.comPDT Partners LLC Acquires 32,083 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)PDT Partners LLC boosted its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 279.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,583 shares of the company's stock after acquiring an addMay 2, 2025 | marketbeat.comRhythm Pharmaceuticals (RYTM) Projected to Post Earnings on WednesdayRhythm Pharmaceuticals (NASDAQ:RYTM) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-rhythm-pharmaceuticals-inc-stock/)May 2, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells $438,964.60 in StockMay 2, 2025 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD boosted its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 24.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 685,152 shares of the compMay 2, 2025 | marketbeat.comFirst Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)First Trust Advisors LP grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 118,337 shares of the company's stock after buying an additional 47,575 shares during the period. FirstMay 2, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by LPL Financial LLCLPL Financial LLC trimmed its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 50.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,175 shares of the company's stock after selling 4,323May 2, 2025 | marketbeat.comDark Forest Capital Management LP Takes $292,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Dark Forest Capital Management LP bought a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 5,211 shares of the company's stMay 1, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Position Lifted by Lord Abbett & CO. LLCLord Abbett & CO. LLC grew its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 56.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 160,651 shares of the company's stocApril 30, 2025 | marketbeat.comArtia Global Partners LP Makes New $2.80 Million Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Artia Global Partners LP acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company's stock, valued at apApril 29, 2025 | marketbeat.comNatixis Has $56,000 Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Natixis lowered its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 91.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 997 shares of the company's stock afterApril 28, 2025 | marketbeat.comWells Fargo & Company MN Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Wells Fargo & Company MN raised its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 26.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 37,324 shares of the company's stock after acquiApril 28, 2025 | marketbeat.comBarclays PLC Has $7.58 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Barclays PLC boosted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 27.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 135,397 shares of the company's stock after buying an additional 29,000 shares during the periodApril 26, 2025 | marketbeat.comLegal & General Group Plc Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Legal & General Group Plc decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 7.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,803 shares of the company's stock after selling 4,April 26, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $74.92 Average Target Price from AnalystsApril 26, 2025 | americanbankingnews.comHood River Capital Management LLC Raises Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Hood River Capital Management LLC grew its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 643,691 shares of the comApril 25, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Buy" by BrokeragesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been given a consensus recommendation of "Buy" by the thirteen ratings firms that are presently covering the company, MarketBeat reports. Thirteen analysts have rated the stock with a buy rating. The average twelve-month target priceApril 25, 2025 | marketbeat.comSilverarc Capital Management LLC Grows Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Silverarc Capital Management LLC raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 7.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 273,896 shares of the comApril 24, 2025 | marketbeat.comDiadema Partners LP Buys New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Diadema Partners LP purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 75,000 shares of the company's stock, valued at approximApril 24, 2025 | marketbeat.comXTX Topco Ltd Purchases Shares of 7,605 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)XTX Topco Ltd acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 7,605 shares of the company's stock, valued at approximately $426,000. OtherApril 24, 2025 | marketbeat.comRhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025April 23, 2025 | globenewswire.comRock Springs Capital Management LP Sells 65,375 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Rock Springs Capital Management LP cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,162,718 sApril 23, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Holdings Increased by Invesco Ltd.Invesco Ltd. raised its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 14.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 302,846 shares of the company's stock after buying an additional 38,429April 22, 2025 | marketbeat.comMarshall Wace LLP Boosts Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Marshall Wace LLP grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 70.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 692,803 shares of the company's stock after purchasing an additioApril 21, 2025 | marketbeat.com6,854 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Farringdon Capital Ltd.Farringdon Capital Ltd. acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 6,854 shares of the company's stock, valued at approximately $38April 20, 2025 | marketbeat.comQ2 EPS Estimates for RYTM Lifted by Needham & Company LLCRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Equities research analysts at Needham & Company LLC lifted their Q2 2025 EPS estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Monday, April 14th. Needham & Company LLC analyst J. StrinApril 19, 2025 | marketbeat.comNeedham & Company LLC Predicts RYTM FY2027 EarningsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Analysts at Needham & Company LLC increased their FY2027 earnings estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Monday, April 14th. Needham & Company LLC analyst J. Stringer now antApril 18, 2025 | marketbeat.comEAM Global Investors LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)EAM Global Investors LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 56,936 shares of the company's stock, vApril 18, 2025 | marketbeat.comEAM Investors LLC Purchases Shares of 63,078 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)EAM Investors LLC acquired a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 63,078 shares of the company's stock, valued at approximately $3,5April 18, 2025 | marketbeat.com144,342 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Walleye Capital LLCWalleye Capital LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 144,342 shares of the company's sApril 18, 2025 | marketbeat.comTrexquant Investment LP Buys Shares of 7,798 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Trexquant Investment LP purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 7,798 shares of the company's stock, valued at approximately $437,000. SeveApril 15, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)JPMorgan Chase & Co. lifted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 224.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 264,585 shares of the company's stock after acquiringApril 14, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 8% - Here's What HappenedRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 8% - Here's WhyApril 11, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells 17,750 Shares of StockApril 11, 2025 | insidertrades.comRhythm Pharmaceuticals price target raised to $68 from $63 at BofAApril 11, 2025 | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 11.9% After Analyst UpgradeRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 11.9% After Analyst UpgradeApril 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $66.00 target price on shares of Rhythm Pharmaceuticals in a report on Tuesday.April 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysCanaccord Genuity Group lifted their target price on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a report on Tuesday.April 10, 2025 | marketbeat.comRhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $80.00 price target (up from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday.April 10, 2025 | marketbeat.comAmerican Century Companies Inc. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)American Century Companies Inc. acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 33,766 shares of the company's stock, valued atApril 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up on Analyst UpgradeRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Analyst UpgradeApril 9, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00 at Wells Fargo & CompanyWells Fargo & Company boosted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a research note on Monday.April 9, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Rating Upgraded by Bank of AmericaBank of America upgraded Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective on the stock in a research note on Monday.April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Takes $1.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)ADAR1 Capital Management LLC bought a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,941 shares of tApril 9, 2025 | marketbeat.com Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼1.130.69▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼177▲RYTM Articles Average Week Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RYTM Stock Free RYTM Stock Alerts